Medically reviewed by Femi Aremu, PharmD Complement 3 glomerulopathy (C3G) is a rare type of kidney disease. There are two types: C3 glomerulonephritis (C3GN) and dense deposit disease (DDD).C3GN is ...

Studies of brain injuries and electrical stimulation seemed to bear this out. Damaging the Broca’s area, for instance, interfered with speech, and stimulating specific tissues could lead to specific ...

The involvement of glial cells in Alzheimer's disease (AD) has been mostly viewed as a secondary adaptive response to ...

A new study shows that internet-delivered cognitive behavioral therapy (ICBT) can effectively reduce asthma-related anxiety ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of ...

Omeros Corporation, an innovative biotechnology company, announced that the US Food and Drug Administration (FDA) has approved Yartemlea (narsoplimab-wuug) for the treatment of hematopoietic stem cell ...

(RTTNews) - Omeros Corporation (OMER) today announced that the FDA has approved YARTEMLEA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and ...

Omeros has won U.S. Food and Drug Administration approval of its Yartemlea treatment for an often-fatal complication of stem-cell transplants. Omeros on Wednesday said the approval covers Yartemlea ...

YARTEMLEA is the first and only approved lectin pathway inhibitor. YARTEMLEA selectively inhibits MASP-2, the effector enzyme of the lectin pathway, blocking pathway activation while preserving ...